Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer ...

Patients were stratified into 4 risk groups based on recent heart failure hospitalization (HFH) and use of loop diuretics. 1 ...

Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite ...

Nemolizumab significantly and safely improved itch and skin lesions for up to 2 years in patients with moderate to severe prurigo nodularis.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, ...

Making clinical trials easier to find for clinicians and making protocols for entering clinical trials more lenient can help ...

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to ...

Panelists discuss how insurance challenges impact spinal muscular atrophy (SMA) care, with prior authorizations becoming more ...

Panelists discuss how combination therapies targeting different aspects of spinal muscular atrophy (SMA), such as myostatin ...